SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cutting the cost of drug development?
3 references·6 citing·35 second hop
Cutting the cost of drug development? (2004)Cutting the cost of drug development?The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs (2000)Randomized, Controlled Trials…Returns to R&D on new drug introductions in the 1980s (1994)Returns to R&D on new drug in…Clinician guidance in digital therapeutics for panic disorder: Meta-analytic dissection and implications for regulatory framing and scalable deployment (2025)Clinician guidance in digital…The risks of risk aversion in drug regulation (2013)The risks of risk aversion in…The Impact of Effective Patents on Future Innovations in Nanomedicine (2012)The Impact of Effective Paten…The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies (2011)The Cost-Effectiveness of Dru…Drug discovery management, small is still beautiful: Why a number of companies get it wrong (2011)Drug discovery management, sm…Making a difference: 30 years of TDR (2008)Making a difference: 30 years…UNDP/World Bank/WHO special programme for research and training in tropical diseases (TDR) (1989)Tropical disease research: progress 1975-94; highlights 1993-94. Twelfth programme report of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). (1995)Drug development for neglected diseases: a deficient market and a public-health policy failure (2002)Protecting new ideas and inventions in nanomedicine with patents (2005)Will the nanomedicine “patent land grab” thwart commercialization? (2005)Patents and Nanomedicine (2007)Pledging Patent Rights for Fighting Against the COVID-19: From the Ethical and Efficiency Perspective (2021)Lessons from 60 years of pharmaceutical innovation (2009)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Drug discovery in the next decade: innovation needed ASAP (2011)“Collaborative Innovation”—Regaining the Edge in Drug Discovery (2013)Clusters and the New Economics of Competition (2014)Cost of innovation in the pharmaceutical industry (1991)Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)An R&D Race with Knowledge Accumulation (2003)Generic competition and market exclusivity periods in pharmaceuticals (2007)The Pharmaceutical Industry (2013)On the Misuse of Accounting Rates of Return to Infer Monopoly Profits (2016)On the Elicitation of Preferences for Alternative Therapies (1982)Trust, Emotion, Sex, Politics, and Science: Surveying the Risk‐Assessment Battlefield (1999)Thinking, Fast and Slow (2011)All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study (2010)Demythologizing the high costs of pharmaceutical research (2011)Meta-analysis in clinical trials (1986)Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials (1995)Evaluating non-randomised intervention studies (2003)Contradicted and Initially Stronger Effects in Highly Cited Clinical Research (2005)External validity of randomised controlled trials: “To whom do the results of this trial apply?” (2005)Mediators and Mechanisms of Change in Psychotherapy Research (2007)Diagnostic and Statistical Manual of Mental Disorders (2013)RoB 2: a revised tool for assessing risk of bias in randomised trials (2019)Efficacy and safety of a mobile app–based, flexible-schedule digital therapeutic intervention versus psychoeducation for panic disorder: An open-label randomized controlled trial (2026)Can the pharmaceutical industry reduce attrition rates? (2004)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)
this work references cited by second hop

References

  • 2003The price of innovation: new estimates of drug development costs4,264 cited
  • 2000Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs3,561 cited
  • 1994Returns to R&D on new drug introductions in the 1980s197 cited

Cited by

  • 2013The risks of risk aversion in drug regulation115 cited
  • 2011The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies76 cited
  • 2008Making a difference: 30 years of TDR28 cited
  • 2011Drug discovery management, small is still beautiful: Why a number of companies get it wrong27 cited
  • 2012The Impact of Effective Patents on Future Innovations in Nanomedicine19 cited
  • 2025Clinician guidance in digital therapeutics for panic disorder: Meta-analytic dissection and implications for regulatory framing and scalable deployment3 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work